Land: Storbritannia
Språk: engelsk
Kilde: MHRA (Medicines & Healthcare Products Regulatory Agency)
Fibrinogen; Thrombin; Calcium chloride; Aprotinin
Baxter Healthcare Ltd
B02BC30
Fibrinogen; Thrombin; Calcium chloride; Aprotinin
91mg/1ml ; 500unit/1ml ; 40micromol/1ml ; 3000Kallikrein inactivator unit/1ml
Solution for sealant
Epilesional
No Controlled Drug Status
Never Valid To Prescribe As A VMP
BNF: ; GTIN: 05413760350059
OBJECT 1 TISSEEL READY TO USE SOLUTIONS FOR SEALANT Summary of Product Characteristics Updated 01-Apr-2015 | Baxter Healthcare Ltd 1. Name of the medicinal product TISSEEL Ready to use Solutions for Sealant 2. Qualitative and quantitative composition Component 1: Sealer Protein Solution Human Fibrinogen (Clottable Protein) 91 mg (1) /ml Aprotinin (synthetic) 3000 KIU (2) /ml Component 2: Thrombin Solution Human Thrombin 500 IU (3) /ml Calcium Chloride 40 μmol/ml 1 Contained in a total protein concentration of 110.5 mg/ml 2 1 EPU (European Pharmacopoeia Unit) corresponds to 1800 KIU (Kallidinogenase Inactivator Unit) 3 Thrombin activity is calculated using the current WHO International Standard for Thrombin. For excipients, see section 6.1. 1 prefilled double chamber syringe which contains Sealer Protein Solution (with synthetic Aprotinin), deep frozen 1 ml, 2 ml, or 5 ml, in one chamber and Thrombin Solution (with Calcium Chloride), deep frozen 1 ml, 2 ml, or 5 ml, in the other chamber results in 2 ml, 4 ml, or 10 ml total volume of product ready for use. 3. Pharmaceutical form Solutions for Sealant Colourless to pale yellow and clear to slightly turbid solutions. 4. Clinical particulars 4.1 Therapeutic indications Supportive treatment where standard surgical techniques are insufficient - for improvement of hemostasis (see section 5.1) - as a tissue glue to promote adhesion/sealing, or as suture support: - in gastrointestinal anastomoses - in neurosurgery where contact with cerebro-spinal fluid or dura mater may occur - For mesh fixation in hernia repair, as an alternative or adjunct to sutures or staples. 4.2 Posology and method of administration The use of TISSEEL is restricted to experienced surgeons who have been trained in the use of TISSEEL. POSOLOGY The amount of TISSEEL Ready to use to be applied and the frequency of application should always be oriented towards the underlying clinical needs for the patient. The dose to be applied is governed by variables including, but not limited to, the type of surgic Les hele dokumentet